MedPath

Fast Titration in the Treatment of Schizophrenia, Taiwan

Phase 3
Completed
Conditions
Schizophrenia
Registration Number
NCT00304473
Lead Sponsor
AstraZeneca
Brief Summary

Assess the efficacy of a fast titration of quetiapine to the current titration approved by the regulatory authorities.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Signed informed consent, at least 18 years old, inpatients with relapse Schizophrenia all subtypes, and with a CGI (Clinical Global Impression) score >=4.
Exclusion Criteria
  • Pregnancy or breast-feeding, patients treated with Clozapine within 28 days of randomization, patients with a known arrhythmia, any psychotic disorders not defined in the inclusion criteria.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Compare the safety and tolerability of a fast titration of quetiapine to the current titration approved by the regulatory authorities.
Secondary Outcome Measures
NameTimeMethod
Assess the efficacy of a fast titration of quetiapine to the current titration approved by the regulatory authorities.

Trial Locations

Locations (1)

Research Site

🇨🇳

Taoyuan, Taiwan

© Copyright 2025. All Rights Reserved by MedPath